Short-term Variability of Repolarization Is Superior to Other Repolarization Parameters in the Evaluation of Diverse Antiarrhythmic Interventions in the Chronic Atrioventricular Block Dog - PubMed
Review
Short-term Variability of Repolarization Is Superior to Other Repolarization Parameters in the Evaluation of Diverse Antiarrhythmic Interventions in the Chronic Atrioventricular Block Dog
Alexandre Bossu et al. J Cardiovasc Pharmacol. 2017 Jun.
Abstract
Short-term variability (STV), to quantify beat-to-beat variability of repolarization, is a surrogate parameter that reliably identifies proarrhythmic risk in preclinical models. Examples include not only the use in the chronic atrioventricular block (CAVB) dog model whereby it was developed but also in vulnerable patients with heart failure or drug-induced long QT syndrome. In the CAVB dog model, STV can specifically distinguish between safe and unsafe drugs in proarrhythmic screening. Conversely, this dog model also offers the possibility to evaluate antiarrhythmic strategies in a setting of Torsades de Pointes (TdP) induction with a standard IKr inhibitor. The different antiarrhythmic interventions studied in suppression and prevention of drug-induced TdP in vivo in the CAVB dog model and in vitro in canine ventricular cardiomyocytes are described in this overview. We provide evidence that STV predicts the magnitude of antiarrhythmic effect against TdP better than other repolarization parameters in both suppression and prevention conditions. Moreover, suppression and prevention experiments revealed the same level of antiarrhythmic efficacy, whereas cellular experiments seem more sensitive in comparison with drug testing in vivo. Together, these observations suggest that STV could be used as a consistent indicator to rank efficacy of antiarrhythmic interventions in a number of conditions.
Conflict of interest statement
The authors report no conflicts of interest.
Figures

A, Arrhythmogenesis in the CAVB dog model. B, Suppression and prevention experimental setups for antiarrhythmic drug evaluation. Lines define intervals during which arrhythmias were monitored to determine TdP inducibility and AS at corresponding periods. Dots define timepoints at which electrophysiological parameters (ECG intervals, MAPD, and STV) were measured. For the proarrhythmic challenge period, they were measured before incidence of the first ectopic beat or (if possible) TdP episode. In the prevention experiments, in the absence of arrhythmias, these parameters were measured at the end of the proarrhythmic challenge infusion (15 minutes). C, Induction of EADs by a proarrhythmic challenge in isolated canine ventricular cardiomyocytes. EADs occur under conditions of increased action potential duration and STV of repolarization. AS, arrhythmia score; MAPD, monophasic action potential duration; STV, short-term variability of repolarization; X, End of antiarrhythmic drug in suppression experiment; Y, end of antiarrhythmic drug in prevention experiment; EB, ectopic beat; TdP, Torsade de Pointes; EADs, early afterdepolarizations.

Temporal dispersion of repolarization (STV) is superior to repolarization (QTc) and its spatial (interventricular ΔMAPD) dispersion parameters in reflecting the magnitude of antiarrhythmic effect in suppression (A) and prevention (B) experiments against TdP arrhythmias. Moderate antiarrhythmic effect by low-dose levcromakalim was accompanied by the reduction of STV but not of other repolarization parameters (QTc and ∆MAPD). Subsequent administration of high-dose levcromakalim exerted stronger antiarrhythmic activity associated with a further STV reduction. Arrhythmias are plotted as percentage (number of TdP observed/number of experiments). Electrophysiological parameters: values are represented as mean ± SD. QTc, QT corrected for heart rate (van de Water formula); STV of repolarization (derived from LV MAPD); ΔMAPD, interventricular dispersion of repolarization (determined as LV−RV MAPD).

STV of repolarization strongly indicates the pharmacological antiarrhythmic efficacy in suppression (A) and prevention (B) experiments. STV values (dots), depicted for suppression (after antiarrhythmic drug administration) and prevention (after dofetilide administration) experiments are represented as mean ± SD. AS (bars) is expressed as mean ± SD. TdP inducibility is indicated as number of dogs with TdP/number of experiments. nq: not quantifiable. STV, short-term variability of repolarization (derived from LV MAPD).
Similar articles
-
van Weperen VYH, Bossu A, Vos MA. van Weperen VYH, et al. J Cardiovasc Pharmacol. 2019 Dec;74(6):499-507. doi: 10.1097/FJC.0000000000000748. J Cardiovasc Pharmacol. 2019. PMID: 31738198 Review.
-
Vernakalant is devoid of proarrhythmic effects in the complete AV block dog model.
Varkevisser R, van der Heyden MA, Tieland RG, Beekman JD, Vos MA. Varkevisser R, et al. Eur J Pharmacol. 2013 Nov 15;720(1-3):49-54. doi: 10.1016/j.ejphar.2013.10.054. Epub 2013 Nov 5. Eur J Pharmacol. 2013. PMID: 24211677
-
Thomsen MB, Volders PG, Beekman JD, Matz J, Vos MA. Thomsen MB, et al. J Am Coll Cardiol. 2006 Sep 19;48(6):1268-76. doi: 10.1016/j.jacc.2006.05.048. Epub 2006 Aug 28. J Am Coll Cardiol. 2006. PMID: 16979017
-
Bossu A, Kostense A, Beekman HDM, Houtman MJC, van der Heyden MAG, Vos MA. Bossu A, et al. Pharmacol Res. 2018 Jul;133:132-140. doi: 10.1016/j.phrs.2018.05.001. Epub 2018 May 16. Pharmacol Res. 2018. PMID: 29753687
-
The canine model with chronic, complete atrio-ventricular block.
Oros A, Beekman JD, Vos MA. Oros A, et al. Pharmacol Ther. 2008 Aug;119(2):168-78. doi: 10.1016/j.pharmthera.2008.03.006. Epub 2008 Apr 6. Pharmacol Ther. 2008. PMID: 18514320 Review.
Cited by
-
IKs Activator ML277 Mildly Affects Repolarization and Arrhythmic Outcome in the CAVB Dog Model.
van Bavel JJA, Beekman HDM, Smoczyńska A, van der Heyden MAG, Vos MA. van Bavel JJA, et al. Biomedicines. 2023 Apr 11;11(4):1147. doi: 10.3390/biomedicines11041147. Biomedicines. 2023. PMID: 37189765 Free PMC article.
-
van Bavel JJA, Pham C, Beekman HDM, Houtman MJC, Bossu A, Sparidans RW, van der Heyden MAG, Vos MA. van Bavel JJA, et al. Front Cardiovasc Med. 2022 Aug 3;9:956538. doi: 10.3389/fcvm.2022.956538. eCollection 2022. Front Cardiovasc Med. 2022. PMID: 35990966 Free PMC article.
-
Bossu A, Houtman MJC, Meijborg VMF, Varkevisser R, Beekman HDM, Dunnink A, de Bakker JMT, Mollova N, Rajamani S, Belardinelli L, van der Heyden MAG, Vos MA. Bossu A, et al. Br J Pharmacol. 2018 Jun;175(12):2470-2482. doi: 10.1111/bph.14217. Epub 2018 May 6. Br J Pharmacol. 2018. PMID: 29582428 Free PMC article.
-
Animal models of arrhythmia: classic electrophysiology to genetically modified large animals.
Clauss S, Bleyer C, Schüttler D, Tomsits P, Renner S, Klymiuk N, Wakili R, Massberg S, Wolf E, Kääb S. Clauss S, et al. Nat Rev Cardiol. 2019 Aug;16(8):457-475. doi: 10.1038/s41569-019-0179-0. Nat Rev Cardiol. 2019. PMID: 30894679 Review.
-
Orosz A, Baczkó I, Nyiraty S, Körei AE, Putz Z, Takács R, Nemes A, Várkonyi TT, Balogh L, Ábrahám G, Kempler P, Papp JG, Varró A, Lengyel C. Orosz A, et al. Front Endocrinol (Lausanne). 2017 Jun 13;8:129. doi: 10.3389/fendo.2017.00129. eCollection 2017. Front Endocrinol (Lausanne). 2017. PMID: 28659867 Free PMC article.
References
-
- Huikuri HV, Castellanos A, Myerburg RJ. Sudden death due to cardiac arrhythmias. N Engl J Med. 2001;345:1473–1482. - PubMed
-
- Moss AJ, Zareba W, Hall WJ, et al. Multicenter automatic defibrillator implantation trial III. prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346:877–883. - PubMed
-
- Bardy GH, Lee KL, Mark DB, et al. Sudden cardiac death in heart failure trial I. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352:225–237. - PubMed
-
- Koller MT, Schaer B, Wolbers M, et al. Death without prior appropriate implantable cardioverter-defibrillator therapy: a competing risk study. Circulation. 2008;117:1918–1926. - PubMed
-
- Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The cardiac arrhythmia suppression trial. N Engl J Med. 1991;324:781–788. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources